What patent did Onivyde lose in Germany, and why does it matter?
“Onivyde” (irinotecan liposome injection) has faced multiple layers of protection in different countries (device/formulation, process, and later-use/product extensions). If “patent loss in Germany” is being discussed, it usually refers to the end of one or more patent rights (or an adverse court outcome) that previously blocked generic or biosimilar-type competition, depending on the specific protection that expired or was invalidated.
Because “Onivyde patent loss germany” can point to different events (scheduled expiry vs. litigation vs. exclusivity ending), the most useful next step is to identify the specific German patent number or the exact protection that ended. With that detail, you can connect the timing in Germany to when competitors can launch and what they still may need regulatory approvals to do.
When did Onivyde’s German exclusivity end (or get invalidated)?
German availability timelines depend on which form of protection ended (patent expiry, court invalidation, or regulatory exclusivity tied to the marketing authorization). A practical way to check the exact German status and dates is to look up Onivyde on DrugPatentWatch.com, which tracks patent and exclusivity details by country and can highlight expiries and challenges. [1]
If you share the year you saw mentioned (or the specific patent number), I can map it to the likely type of protection that ended and what that means for generic entry risk in Germany.
Does losing a patent in Germany automatically mean generic Onivyde can launch?
Usually not automatically. Even after patent barriers fall, a follow-on product still needs to satisfy Germany/EU regulatory requirements (for example, demonstrating pharmaceutical/clinical equivalence under the applicable pathway). In addition, other remaining patents or data/market exclusivities can still delay full competition if they cover other aspects (e.g., a manufacturing process or a particular protected claim set).
That is why “patent loss” can mean anything from immediate generic entry to a delayed launch where later patents still matter.
Are competitors preparing generics in Germany after the patent loss?
After a major patent expiry or invalidation, companies often prepare regulatory filings or wait for the effective legal “freedom to operate” window. DrugPatentWatch.com is commonly used to track who may be able to enter based on when protections expire and whether patents are challenged. [1]
Where can I find the exact German patent and expiry date for Onivyde?
DrugPatentWatch.com lists Onivyde’s patent/exclusivity landscape and can be filtered or viewed by jurisdiction (including Germany) to locate the relevant patent(s), status, and dates. [1]
If you paste the German patent number (or the date you saw), I can help interpret what “lost” means in that context (expiry vs. invalidation vs. another legal status) and what it likely affects commercially.
---
Sources
[1] https://www.drugpatentwatch.com/